fb-pixel Skip to main content

Cambridge biopharmaceutical company Acceleron Pharma Inc. on Wednesday registered for an initial public offering of stock that could raise up to $74.8 million.

The number of shares to be offered and the price range for the offering have not been determined, the company said.

Five Massachusetts biotechnology start-ups had gone public so far this year. And Foundation Medicine of Cambridge, a supplier of genomic testing for cancer patients, recently filed plans with regulators to raise $86.25 million by going public.

In March, Acceleron said that the Food and Drug Administration had granted orphan drug designation for its ACE-536 drug candidate as a potential treatment for two rare blood disorders.


Acceleron makes therapies for cancer and rare diseases. It said it lost nearly $32.6 million on revenues of about $15.3 million in 2012.

Citigroup and Leerink Swann LLC will act as joint book-running managers for the offering. Piper Jaffray & Co. will act as lead manager, and JMP Securities will act as co-manager for the offering, Acceleron said.

Chris Reidy

Chris Reidy can be reached at reidy@globe.com.